Kailera Therapeutics (NASDAQ:KLRA) Releases Earnings Results, Misses Estimates By $0.35 EPS

Kailera Therapeutics (NASDAQ:KLRA) announced its quarterly earnings data on Wednesday. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35), FiscalAI reports.

Kailera Therapeutics Stock Performance

Shares of Kailera Therapeutics stock traded up $0.03 during midday trading on Friday, reaching $18.00. 194,340 shares of the company’s stock traded hands, compared to its average volume of 702,514. The company has a market capitalization of $2.33 billion and a P/E ratio of -0.00. The company’s 50 day moving average is $19.46. Kailera Therapeutics has a 12 month low of $16.39 and a 12 month high of $28.23.

Analyst Upgrades and Downgrades

KLRA has been the subject of several analyst reports. Leerink Partners assumed coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 target price for the company. JPMorgan Chase & Co. assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target on the stock. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Jefferies Financial Group began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $48.00 price objective for the company. Finally, TD Cowen started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Kailera Therapeutics currently has an average rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.